Emapalumab

依马利尤单抗

Report date: 2026/05/02 20:00:18
First In Class

Base Information

Drug NameEmapalumab
Drug Alias Name依帕伐单抗Emapalumab-IzsgGamifantNI-0501
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterferon gamma inhibitors
TargetsInterferon gamma
Therapy Area/IndicationsRejection of lung transplantationCytopeniaRare Diseases +[14] 
Global Approved IndicationsLymphohistiocytosis, Hemophagocytic
Approved Indications in ChinaLymphohistiocytosis, Hemophagocytic
Original Approved Country/TerritoryUnited States
Original Approved Date2018/11/20
Country/TerritoryCzechiaBelgiumCanada +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovimmune Sa
China Registration ClassN/A

Develop Information

Active CompaniesSwedish Orphan Biovitrum AgSobiUniversity Of California San Francisco +[11] 
Inactive CompaniesLight Chain Bioscience Ltd
Active IndicationsRejection of lung transplantationCytopeniaRare Diseases +[12] 
Inactive IndicationsImmune System DiseasesArthritis, Juvenile

Other Information

ATC CodeL04AG09
Related LinksWikipediaDrugBankKEGG